Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for XXXX ?: A cohort study.

@entity1169 @entity1 @entity7492 @entity551 @entity65
BACKGROUND: Although consensus guidelines for pretreatment evaluation and monitoring of @entity1169 therapy in @entity1 with @entity7492 ( @entity7492 ) have been formulated, little is known about the cardiovascular side effects. OBJECTIVES: We sought to analyze cardiovascular evaluations in @entity1 with @entity7492 at baseline and during treatment with an oral beta-blocker. METHODS: Data from 109 @entity1 with @entity7492 were retrospectively analyzed. @entity1 and family history, pretreatment electrocardiogram (ECG), heart rate, and blood pressure were evaluated before initiation of beta-blocker therapy. Blood pressure and standardized questionnaires addressing side effects were evaluated during treatment. RESULTS: Questionnaire analyses (n  = 83) identified 3 cases with a family history of @entity65 in first-degree relatives. ECG findings were normal in each case and no serious complication of therapy occurred. ECG abnormalities were found in 6.5% of @entity1 but there were no contraindications to beta-blocker therapy and no major complications. @entity551 in 9 @entity1 did not require therapy adjustment. In all, 88 parents (81%) reported side effects during beta-blocker treatment. LIMITATIONS: The relatively small @entity1 cohort is a limitation. CONCLUSION: Pretreatment ECG is of limited value for @entity1 with an unremarkable cardiovascular history and a normal heart rate and blood pressure. @entity551 may occur during treatment.
